Patents by Inventor Justin Anglin

Justin Anglin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for treating or preventing bacterial infections
    Patent number: 12286418
    Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.
    Type: Grant
    Filed: June 20, 2020
    Date of Patent: April 29, 2025
    Assignee: Baylor College of Medicine
    Inventors: Timothy Palzkill, Doris Taylor, Justin Anglin, Nicholas Simmons, John Faver, Yong Wang, Zhuang Jin, Martin Matzuk
  • BET SUBFAMILY INHIBITORS AND METHODS USING SAME
    Publication number: 20240158355
    Abstract: In one aspect, the present disclosure provides compounds which inhibit bromodomain testis (BRDT). In some embodiments, the compounds inhibit bromodomain-2 of BRDT. In another aspect, the present disclosure provides a method of inhibiting BRDT in a male subject, the method comprising administering to the male subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method provides a contraceptive effect in the male subject.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 16, 2024
    Inventors: Martin Matzuk, Zhifeng Yu, Angela Ku, Justin Anglin, Feng Li, Damian Young, Ying-Chu Chen, Melek Ucisik, John Faver, Stephen Palmer, Rajesh Sharma, Choel Kim
  • Compounds and Methods for Treating or Preventing Bacterial Infections
    Publication number: 20220267303
    Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.
    Type: Application
    Filed: June 20, 2020
    Publication date: August 25, 2022
    Inventors: Timothy Palzkill, Doris Taylor, Justin Anglin, Nicholas Simmons, John Faver, Yong Wang, Zhuang Jin